UA63896C2 - Morphogenetic material for repairing cartilage and bone and method for treating - Google Patents
Morphogenetic material for repairing cartilage and bone and method for treating Download PDFInfo
- Publication number
- UA63896C2 UA63896C2 UA98063095A UA98063095A UA63896C2 UA 63896 C2 UA63896 C2 UA 63896C2 UA 98063095 A UA98063095 A UA 98063095A UA 98063095 A UA98063095 A UA 98063095A UA 63896 C2 UA63896 C2 UA 63896C2
- Authority
- UA
- Ukraine
- Prior art keywords
- bone
- cartilage
- morphogenetic
- polyoxyethylene
- protein
- Prior art date
Links
- 210000000988 bone and bone Anatomy 0.000 title claims abstract description 42
- 210000000845 cartilage Anatomy 0.000 title claims abstract description 36
- 239000000463 material Substances 0.000 title claims abstract description 27
- 238000000034 method Methods 0.000 title claims abstract description 16
- 230000001002 morphogenetic effect Effects 0.000 title claims description 19
- 229920002503 polyoxyethylene-polyoxypropylene Polymers 0.000 claims abstract description 36
- 239000007864 aqueous solution Substances 0.000 claims abstract description 12
- 229920001451 polypropylene glycol Polymers 0.000 claims abstract description 11
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical group C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 claims abstract description 10
- 108010007726 Bone Morphogenetic Proteins Proteins 0.000 claims description 32
- 102000007350 Bone Morphogenetic Proteins Human genes 0.000 claims description 32
- 229940112869 bone morphogenetic protein Drugs 0.000 claims description 28
- 101100472152 Trypanosoma brucei brucei (strain 927/4 GUTat10.1) REL1 gene Proteins 0.000 claims description 12
- 108010049931 Bone Morphogenetic Protein 2 Proteins 0.000 claims description 9
- 102100024506 Bone morphogenetic protein 2 Human genes 0.000 claims description 9
- 239000003795 chemical substances by application Substances 0.000 claims description 8
- 208000010392 Bone Fractures Diseases 0.000 claims description 6
- 241001465754 Metazoa Species 0.000 claims description 4
- 230000002441 reversible effect Effects 0.000 abstract description 7
- 230000001939 inductive effect Effects 0.000 abstract description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 abstract 6
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 abstract 3
- 239000000411 inducer Substances 0.000 abstract 3
- 238000001727 in vivo Methods 0.000 abstract 1
- 230000006698 induction Effects 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 description 30
- 102000004169 proteins and genes Human genes 0.000 description 28
- 238000002347 injection Methods 0.000 description 20
- 239000007924 injection Substances 0.000 description 20
- 239000004174 erythrosine Substances 0.000 description 16
- 239000000243 solution Substances 0.000 description 16
- 150000001413 amino acids Chemical class 0.000 description 13
- 230000009466 transformation Effects 0.000 description 12
- 239000000499 gel Substances 0.000 description 11
- 210000003205 muscle Anatomy 0.000 description 10
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 9
- 235000010469 Glycine max Nutrition 0.000 description 9
- 210000004027 cell Anatomy 0.000 description 8
- 239000007788 liquid Substances 0.000 description 8
- 239000000203 mixture Substances 0.000 description 8
- 244000068988 Glycine max Species 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 7
- 108010035532 Collagen Proteins 0.000 description 6
- 102000008186 Collagen Human genes 0.000 description 6
- 108020004414 DNA Proteins 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 6
- 229920001436 collagen Polymers 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 210000000548 hind-foot Anatomy 0.000 description 6
- 210000003000 inclusion body Anatomy 0.000 description 6
- 239000007787 solid Substances 0.000 description 6
- 239000004480 active ingredient Substances 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 239000012634 fragment Substances 0.000 description 5
- 238000000746 purification Methods 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 108091028043 Nucleic acid sequence Proteins 0.000 description 4
- 230000034127 bone morphogenesis Effects 0.000 description 4
- 230000001419 dependent effect Effects 0.000 description 4
- 239000013604 expression vector Substances 0.000 description 4
- 239000000178 monomer Substances 0.000 description 4
- 108020004707 nucleic acids Proteins 0.000 description 4
- 102000039446 nucleic acids Human genes 0.000 description 4
- 150000007523 nucleic acids Chemical class 0.000 description 4
- 230000001191 orthodromic effect Effects 0.000 description 4
- 239000013612 plasmid Substances 0.000 description 4
- 229920000642 polymer Polymers 0.000 description 4
- 210000000689 upper leg Anatomy 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
- 210000001185 bone marrow Anatomy 0.000 description 3
- 239000004202 carbamide Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000010276 construction Methods 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 210000000963 osteoblast Anatomy 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 238000010186 staining Methods 0.000 description 3
- 238000011477 surgical intervention Methods 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 206010002091 Anaesthesia Diseases 0.000 description 2
- 108020004705 Codon Proteins 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 125000000539 amino acid group Chemical group 0.000 description 2
- 230000037005 anaesthesia Effects 0.000 description 2
- 230000003459 anti-dromic effect Effects 0.000 description 2
- 229920002988 biodegradable polymer Polymers 0.000 description 2
- 239000004621 biodegradable polymer Substances 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000002805 bone matrix Anatomy 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 230000007355 cartilage morphogenesis Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 229920001577 copolymer Polymers 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 238000010353 genetic engineering Methods 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 229910052588 hydroxylapatite Inorganic materials 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 230000011164 ossification Effects 0.000 description 2
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 2
- 229920000747 poly(lactic acid) Polymers 0.000 description 2
- 239000004626 polylactic acid Substances 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 239000008213 purified water Substances 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- 108091008146 restriction endonucleases Proteins 0.000 description 2
- 230000000717 retained effect Effects 0.000 description 2
- FGDZQCVHDSGLHJ-UHFFFAOYSA-M rubidium chloride Chemical compound [Cl-].[Rb+] FGDZQCVHDSGLHJ-UHFFFAOYSA-M 0.000 description 2
- 230000007928 solubilization Effects 0.000 description 2
- 238000005063 solubilization Methods 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- JZRWCGZRTZMZEH-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N JZRWCGZRTZMZEH-UHFFFAOYSA-N 0.000 description 2
- 239000013598 vector Substances 0.000 description 2
- 229920000936 Agarose Polymers 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical group [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000699802 Cricetulus griseus Species 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 108010053070 Glutathione Disulfide Proteins 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 108010090290 Growth Differentiation Factor 2 Proteins 0.000 description 1
- 102100040892 Growth/differentiation factor 2 Human genes 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- 101710167839 Morphogenetic protein Proteins 0.000 description 1
- RAQQRQCODVNJCK-JLHYYAGUSA-N N-[(4-amino-2-methylpyrimidin-5-yl)methyl]-N-[(E)-5-hydroxy-3-(2-hydroxyethyldisulfanyl)pent-2-en-2-yl]formamide Chemical compound C\C(N(Cc1cnc(C)nc1N)C=O)=C(\CCO)SSCCO RAQQRQCODVNJCK-JLHYYAGUSA-N 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- 108091081024 Start codon Proteins 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 108020005038 Terminator Codon Proteins 0.000 description 1
- 229910001069 Ti alloy Inorganic materials 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 230000002587 anti-hemolytic effect Effects 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 239000002473 artificial blood Substances 0.000 description 1
- 108010045569 atelocollagen Proteins 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 210000003321 cartilage cell Anatomy 0.000 description 1
- 230000022159 cartilage development Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000012459 cleaning agent Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 229920006237 degradable polymer Polymers 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 1
- YPZRWBKMTBYPTK-BJDJZHNGSA-N glutathione disulfide Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@H](C(=O)NCC(O)=O)CSSC[C@@H](C(=O)NCC(O)=O)NC(=O)CC[C@H](N)C(O)=O YPZRWBKMTBYPTK-BJDJZHNGSA-N 0.000 description 1
- 239000000710 homodimer Substances 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 125000001165 hydrophobic group Chemical group 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 230000000622 irritating effect Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000008141 laxative Substances 0.000 description 1
- 229940125722 laxative agent Drugs 0.000 description 1
- 239000003589 local anesthetic agent Substances 0.000 description 1
- 229960005015 local anesthetics Drugs 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 210000001259 mesencephalon Anatomy 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 238000001000 micrograph Methods 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- YPZRWBKMTBYPTK-UHFFFAOYSA-N oxidized gamma-L-glutamyl-L-cysteinylglycine Natural products OC(=O)C(N)CCC(=O)NC(C(=O)NCC(O)=O)CSSCC(C(=O)NCC(O)=O)NC(=O)CCC(N)C(O)=O YPZRWBKMTBYPTK-UHFFFAOYSA-N 0.000 description 1
- 230000036407 pain Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000013600 plasmid vector Substances 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 239000013587 production medium Substances 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- 229940102127 rubidium chloride Drugs 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 229910001256 stainless steel alloy Inorganic materials 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 238000006277 sulfonation reaction Methods 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 239000002700 tablet coating Substances 0.000 description 1
- 238000009492 tablet coating Methods 0.000 description 1
- 235000019157 thiamine Nutrition 0.000 description 1
- 239000011721 thiamine Substances 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000820 toxicity test Toxicity 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 239000001226 triphosphate Substances 0.000 description 1
- 235000011178 triphosphate Nutrition 0.000 description 1
- UNXRWKVEANCORM-UHFFFAOYSA-N triphosphoric acid Chemical compound OP(O)(=O)OP(O)(=O)OP(O)(O)=O UNXRWKVEANCORM-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/14—Macromolecular materials
- A61L27/22—Polypeptides or derivatives thereof, e.g. degradation products
- A61L27/227—Other specific proteins or polypeptides not covered by A61L27/222, A61L27/225 or A61L27/24
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/28—Bones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/30—Joints
- A61F2/30756—Cartilage endoprostheses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1875—Bone morphogenic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/51—Bone morphogenetic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/28—Bones
- A61F2002/2817—Bone stimulation by chemical reactions or by osteogenic or biological products for enhancing ossification, e.g. by bone morphogenetic or morphogenic proteins [BMP] or by transforming growth factors [TGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/30—Joints
- A61F2002/30001—Additional features of subject-matter classified in A61F2/28, A61F2/30 and subgroups thereof
- A61F2002/30003—Material related properties of the prosthesis or of a coating on the prosthesis
- A61F2002/3006—Properties of materials and coating materials
- A61F2002/30062—(bio)absorbable, biodegradable, bioerodable, (bio)resorbable, resorptive
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2210/00—Particular material properties of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
- A61F2210/0004—Particular material properties of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof bioabsorbable
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Organic Chemistry (AREA)
- Transplantation (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Cardiology (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Dermatology (AREA)
- Genetics & Genomics (AREA)
- Toxicology (AREA)
- Rheumatology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Physical Education & Sports Medicine (AREA)
- Diabetes (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Materials For Medical Uses (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP7322402A JPH09143093A (ja) | 1995-11-17 | 1995-11-17 | 軟骨・骨誘導性修復用材料 |
| PCT/JP1996/003333 WO1997018829A1 (fr) | 1995-11-17 | 1996-11-14 | Materiaux inducteurs d'os/de cartilage en vue de leur reparation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UA63896C2 true UA63896C2 (en) | 2004-02-16 |
Family
ID=18143268
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UA98063095A UA63896C2 (en) | 1995-11-17 | 1996-11-14 | Morphogenetic material for repairing cartilage and bone and method for treating |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US6903071B2 (fr) |
| EP (1) | EP0884052B1 (fr) |
| JP (1) | JPH09143093A (fr) |
| KR (1) | KR100458413B1 (fr) |
| CN (1) | CN1165340C (fr) |
| AT (1) | ATE254470T1 (fr) |
| AU (1) | AU712445C (fr) |
| CA (1) | CA2235400C (fr) |
| DE (1) | DE69630811T2 (fr) |
| DK (1) | DK0884052T3 (fr) |
| ES (1) | ES2211993T3 (fr) |
| HK (1) | HK1018205A1 (fr) |
| HU (1) | HU226201B1 (fr) |
| NO (1) | NO325119B1 (fr) |
| NZ (1) | NZ322188A (fr) |
| PT (1) | PT884052E (fr) |
| RU (1) | RU2180234C2 (fr) |
| UA (1) | UA63896C2 (fr) |
| WO (1) | WO1997018829A1 (fr) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH09143093A (ja) * | 1995-11-17 | 1997-06-03 | Hoechst Japan Ltd | 軟骨・骨誘導性修復用材料 |
| US6281195B1 (en) † | 1997-02-07 | 2001-08-28 | Stryker Corporation | Matrix-free osteogenic devices, implants and methods of use thereof |
| US6309659B1 (en) | 1997-09-02 | 2001-10-30 | Gensci Orthobiologics, Inc. | Reverse phase connective tissue repair composition |
| DE60022776T2 (de) * | 1999-10-29 | 2006-08-24 | Childrens Hospital Los Angeles, Los Angeles | Verfahren und material zur hämostase bei knochen |
| US9616150B2 (en) | 1999-10-29 | 2017-04-11 | Children's Hospital Los Angeles | Bone hemostasis method and materials |
| AU1375301A (en) | 1999-11-15 | 2001-05-30 | Bio Syntech Canada Inc | Temperature-controlled and ph-dependant self-gelling biopolymeric aqueous solution |
| US7747332B2 (en) * | 2000-05-08 | 2010-06-29 | International Rehabilitative Sciences, Inc. | Electrical stimulation combined with a biologic to increase osteogenesis |
| DK1294414T3 (da) * | 2000-06-29 | 2006-07-24 | Biosyntech Canada Inc | Præparat og fremgangsmåde til heling og regenerering af brusk og andre væv |
| JP2002306163A (ja) * | 2001-04-11 | 2002-10-22 | Chemo Sero Therapeut Res Inst | 大腸菌を宿主とする遺伝子組換えヒトトロンビンの調製方法 |
| EP1456278B1 (fr) * | 2001-12-21 | 2006-03-08 | IsoTis Orthobiologics, Inc. | Compositions contenant des glycols de polyalkylene a extremites coiffees |
| US7205337B2 (en) * | 2001-12-21 | 2007-04-17 | Isotis Orthobiologics, Inc. | End-capped polymers and compositions containing such compounds |
| EP1512405B1 (fr) * | 2002-05-20 | 2013-08-14 | Otsuka Pharmaceutical Co., Ltd. | Composition contenant de l'adenosine monophosphate pour le traitement du melasma |
| WO2004022120A1 (fr) * | 2002-09-04 | 2004-03-18 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Compositions contenant des cellules de moelle osseuse, une matrice osseuse demineralisee et des polymeres a gelification thermique inverse, destinees a l'induction de la formation osseuse et cartilagineuse |
| TWI367113B (en) | 2003-02-12 | 2012-07-01 | Syncera Inc | Random and non-random alkylene oxide polymer alloy compositions |
| EP2001528A4 (fr) * | 2006-03-23 | 2012-04-04 | Citagenix Inc | Composition ostéoconductrice à phase inverse |
| ES2402672T3 (es) * | 2007-01-25 | 2013-05-07 | Biopharm Gesellschaft Zur Biotechnologischen Entwicklung Von Pharmaka Mbh | Uso del GDF-5 para el mejoramiento o el mantenimiento del aspecto dérmico |
| US8290780B2 (en) | 2009-06-24 | 2012-10-16 | International Business Machines Corporation | Dynamically extending the speech prompts of a multimodal application |
| KR101405104B1 (ko) * | 2011-12-26 | 2014-06-10 | 한남대학교 산학협력단 | 약물의 서방형 방출 특성을 가지는 골 시멘트 |
| US10743996B2 (en) * | 2017-03-24 | 2020-08-18 | Robert L. Bundy | Amnion putty for cartilage repair |
| CN109125791B (zh) * | 2018-09-29 | 2019-08-30 | 广州贝奥吉因生物科技有限公司 | 一种具有促进骨修复功能的可吸收骨蜡及制备方法 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS61277612A (ja) * | 1985-05-31 | 1986-12-08 | Kiyoshi Morikawa | 接種用徐放性組成物 |
| JPH0723322B2 (ja) * | 1985-12-07 | 1995-03-15 | 克之 藤井 | 液状骨形成剤からなる注射液 |
| NZ226171A (en) * | 1987-09-18 | 1990-06-26 | Ethicon Inc | Gel formulation containing polypeptide growth factor |
| US4863732A (en) * | 1987-12-16 | 1989-09-05 | Collagen Corporation | Injectable composition for inductive bone repair |
| US5162430A (en) * | 1988-11-21 | 1992-11-10 | Collagen Corporation | Collagen-polymer conjugates |
| JPH045227A (ja) * | 1990-04-17 | 1992-01-09 | Pharmetrix Corp | 歯周疾患治療システム |
| CA2040460C (fr) * | 1990-05-01 | 1997-06-10 | Tacey X. Viegas | Distribution de medicaments au moyen de gels thermoreversibles |
| AU662155B2 (en) * | 1991-05-10 | 1995-08-24 | Celtrix Pharmaceuticals, Inc. | Targeted delivery of bone growth factors |
| JP3351525B2 (ja) * | 1991-06-21 | 2002-11-25 | ジェネティックス・インスティテュート・インコーポレイテッド | 骨形成性蛋白医薬処方物 |
| EP0551626A1 (fr) * | 1991-12-19 | 1993-07-21 | LEK, tovarna farmacevtskih in kemicnih izdelkov, d.d. | Gel thermoréversible utile comme excipient pharmaceutique pour une formation galénique |
| JPH08502082A (ja) * | 1992-07-02 | 1996-03-05 | コラーゲン コーポレイション | 生体適合性ポリマー結合体 |
| IL110589A0 (en) * | 1993-08-10 | 1994-11-11 | Bioph Biotech Entw Pharm Gmbh | Growth/differentiation factor of the TGF- beta family |
| JP3696265B2 (ja) * | 1994-02-04 | 2005-09-14 | 日本オルガノン株式会社 | 点鼻液剤 |
| DE4423396C2 (de) | 1994-07-04 | 2001-10-25 | Fraunhofer Ges Forschung | Verfahren zum Herstellen einer mikromechanischen Oberflächenstruktur |
| WO1996021427A1 (fr) | 1995-01-09 | 1996-07-18 | Atrix Laboratories, Inc. | Systeme d'administration d'un polymere liquide |
| US5902785A (en) * | 1995-06-06 | 1999-05-11 | Genetics Institute, Inc. | Cartilage induction by bone morphogenetic proteins |
| JPH09143093A (ja) * | 1995-11-17 | 1997-06-03 | Hoechst Japan Ltd | 軟骨・骨誘導性修復用材料 |
-
1995
- 1995-11-17 JP JP7322402A patent/JPH09143093A/ja active Pending
-
1996
- 1996-11-14 HU HU0000411A patent/HU226201B1/hu not_active IP Right Cessation
- 1996-11-14 WO PCT/JP1996/003333 patent/WO1997018829A1/fr active IP Right Grant
- 1996-11-14 US US09/068,253 patent/US6903071B2/en not_active Expired - Fee Related
- 1996-11-14 KR KR10-1998-0703705A patent/KR100458413B1/ko not_active IP Right Cessation
- 1996-11-14 EP EP96938460A patent/EP0884052B1/fr not_active Expired - Lifetime
- 1996-11-14 RU RU98111599/14A patent/RU2180234C2/ru not_active IP Right Cessation
- 1996-11-14 DK DK96938460T patent/DK0884052T3/da active
- 1996-11-14 PT PT96938460T patent/PT884052E/pt unknown
- 1996-11-14 DE DE69630811T patent/DE69630811T2/de not_active Expired - Lifetime
- 1996-11-14 ES ES96938460T patent/ES2211993T3/es not_active Expired - Lifetime
- 1996-11-14 CA CA002235400A patent/CA2235400C/fr not_active Expired - Fee Related
- 1996-11-14 NZ NZ322188A patent/NZ322188A/xx not_active IP Right Cessation
- 1996-11-14 CN CNB961995645A patent/CN1165340C/zh not_active Expired - Fee Related
- 1996-11-14 AU AU75869/96A patent/AU712445C/en not_active Ceased
- 1996-11-14 UA UA98063095A patent/UA63896C2/uk unknown
- 1996-11-14 AT AT96938460T patent/ATE254470T1/de active
-
1998
- 1998-05-15 NO NO19982236A patent/NO325119B1/no not_active IP Right Cessation
-
1999
- 1999-07-23 HK HK99103183A patent/HK1018205A1/xx not_active IP Right Cessation
-
2004
- 2004-07-07 US US10/885,099 patent/US7238657B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| ATE254470T1 (de) | 2003-12-15 |
| HUP0000411A3 (en) | 2005-11-28 |
| CA2235400C (fr) | 2007-12-18 |
| NO982236D0 (no) | 1998-05-15 |
| NZ322188A (en) | 2000-10-27 |
| DK0884052T3 (da) | 2004-03-29 |
| CN1207047A (zh) | 1999-02-03 |
| HU226201B1 (en) | 2008-06-30 |
| AU712445C (en) | 2002-03-28 |
| KR19990067676A (ko) | 1999-08-25 |
| US20020168381A1 (en) | 2002-11-14 |
| EP0884052A4 (fr) | 1999-05-06 |
| US20050013864A1 (en) | 2005-01-20 |
| NO982236L (no) | 1998-06-26 |
| EP0884052A1 (fr) | 1998-12-16 |
| NO325119B1 (no) | 2008-02-04 |
| JPH09143093A (ja) | 1997-06-03 |
| WO1997018829A1 (fr) | 1997-05-29 |
| CA2235400A1 (fr) | 1997-05-29 |
| CN1165340C (zh) | 2004-09-08 |
| DE69630811T2 (de) | 2004-06-17 |
| US6903071B2 (en) | 2005-06-07 |
| DE69630811D1 (de) | 2003-12-24 |
| AU7586996A (en) | 1997-06-11 |
| PT884052E (pt) | 2004-04-30 |
| US7238657B2 (en) | 2007-07-03 |
| HUP0000411A2 (hu) | 2001-04-28 |
| KR100458413B1 (ko) | 2005-04-06 |
| HK1018205A1 (en) | 1999-12-17 |
| EP0884052B1 (fr) | 2003-11-19 |
| ES2211993T3 (es) | 2004-07-16 |
| RU2180234C2 (ru) | 2002-03-10 |
| AU712445B2 (en) | 1999-11-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UA63896C2 (en) | Morphogenetic material for repairing cartilage and bone and method for treating | |
| US6380154B1 (en) | Synthetic proteins for in vivo drug delivery and tissue augmentation | |
| FI119816B (fi) | Eristetyt DNA-sekvenssit, jotka koodaavat jänteen/nivelsiteen kaltaisen kudoksen muodostumista indusoivaa BMP-12- tai BMP-13-proteiinia, sekä niiden sovellukset | |
| CN109568671B (zh) | 一种水凝胶负载细胞的3d骨修复支架及其制备方法 | |
| JP2004041236A (ja) | 骨形成具 | |
| CN112972760B (zh) | 一种负载内皮细胞外基质的3d打印骨缺损修复支架及其制备方法 | |
| JP7542880B2 (ja) | オルガノイドの生体移植用組成物 | |
| CN104800885B (zh) | 一种具有趋化功能的生物活性支架的制备和应用 | |
| CN109069661A (zh) | 利用聚合蛋白共轭物的治疗 | |
| CN104307040B (zh) | 一种组织工程用具控释能力的注射式水凝胶及其应用 | |
| JP2001131086A (ja) | エンドセリンを含む結合組織修復促進組成物および該組成物の調製におけるエンドセリンの使用 | |
| CN114805484B (zh) | 一种自组装多肽、自组装纳米水凝胶及其应用 | |
| KR100358080B1 (ko) | 생리활성물질을 서방화하는 다공성·생분해성 인공장기의제조방법 | |
| EP1844798A1 (fr) | Matériel avec mastic implantable | |
| Huang et al. | Biological activity of self-assembled peptide hydrogel scaffold RADA-RGD and its experimental study of BMP-2 release in vitro | |
| Ross et al. | Multipurpose On‐the‐Spot Peptide‐Based Hydrogels for Skin, Cornea, and Heart Repair | |
| RU2195940C2 (ru) | Способ регенерации суставного хряща | |
| CN112206307B (zh) | 一种可注射的温敏型水凝胶及其制备方法与应用 | |
| JP2001122799A (ja) | プレイオトロフィンを含む結合組織修復促進組成物および該組成物の調製におけるプレイオトロフィンの使用 | |
| KR20190012589A (ko) | 콘드로이틴설페이트가 함유된 젤란검 하이드로겔 조성물 | |
| ES2625654T3 (es) | Un método de producción de componentes nativos, tales como factores de crecimiento o proteínas de la matriz extracelular, mediante cultivo celular de muestras de tejido para la reparación de tejido | |
| WO2019151450A1 (fr) | Substance de culture de cellules nerveuses et agent thérapeutique pour lésion nerveuse | |
| CN114025846A (zh) | 用于治疗关节疾病的药物组合物及其制备方法 | |
| CN116478268A (zh) | Bmp2蛋白保护液、bmp2蛋白制剂及其制备方法 | |
| CN115287257A (zh) | 基于弓形虫外分泌蛋白的成骨诱导分化培养基、制备方法及成骨诱导分化方法 |